Pathology: la/mBC - HR-positive - 1st line (L1);
| la/mBC - HR-positive - 1st line (L1) | |||||
| CALGB 40302, 2014 | EGF30008 (all population), 2009 | EGF30008 (HER2-positive), 2009 | SYSUCC-002, 2022 | ||
| lapatinib plus letrozole | 2 | T1 | T1 | ||
| trastuzumab plus endocrine therapy | 1 | T1 | |||
| lapatinib plus fulvestrant | 1 | T1 | |||
| trastuzumab plus chemotherapy | 0 | T0 | |||
| fulvestrant | 0 | T0 | |||
| letrozole | 0 | T0 | T0 | ||